• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of emborepLink to Publisher's site
EMBO Rep. Sep 15, 2000; 1(3): 225–231.
PMCID: PMC1083726
Reviews
Reviews

Aggresomes and Russell bodies: Symptoms of cellular indigestion?

Abstract

All cells are equipped with a proteolytic apparatus that eliminates damaged, misfolded and incorrectly assembled proteins. The principal engine of cytoplasmic proteolysis, the 26S proteasome, requires that substrates be unfolded to gain access to the active site; consequently, it is relatively ineffective at degrading aggregated proteins. Cellular indigestion occurs when the production of aggregation-prone proteins exceeds the cell’s (or organelle’s) capacity to eliminate them. Cellular pathways that resolve this indigestion exist, but appear to have limited capacities. Russell bodies and aggresomes are manifestations of cellular indigestion in the endoplasmic reticulum and cytoplasmic compartments, respectively, and are often associated with disease.

Introduction

In living cells, proteins are constantly degraded. Proteolysis is essential to maintain metabolic homeostasis; it regulates central biological phenomena including cell proliferation, signaling and antigen presentation (see Kirschner, 1999; Wickner et al., 1999) and serves to eliminate potentially toxic, misfolded and damaged proteins. Proteasomes, barrel-shaped structures in which the active sites of various proteases face the interior cavity, are the major engine of cytoplasmic proteolysis. A cost of this arrangement is the requirement that substrates must be unfolded to be ‘fed’ into the narrow entrance to the interior cavity. Eukaryotic cells face an additional topological problem: since proteasomes are excluded from membrane-bound organelles (Rivett, 1998), these must be equipped with either a distinct proteolytic system within these organelles, or with machinery to export short-lived proteins into the cytosol for degradation.

Quality control in the ER: the cytoplasmic connection

Proteins destined for the extracellular space and the organelles of the central vacuolar system fold in the endoplasmic reticulum (ER). A sophisticated quality control system (Ellgaard et al., 1999) ensures that folding or assembly intermediates are prevented from progressing to the Golgi apparatus, and that misfolded proteins are eventually retro-translocated, or ‘dislocated’, across the ER membrane to the cytosol for proteasomal degradation. The Sec61 complex, which forms a channel called a ‘translocon’ through which nascent proteins are translocated into the ER, also seems to be responsible for dislocation of misfolded proteins (Wiertz et al., 1996; Pilon et al., 1997). This unexpected ‘cytoplasmic connection’ between quality control in the ER and cytosolic proteasomes (Kopito, 1997) has provided an answer to the long debated problem of how myriads of nascent proteins might coexist in the ER lumen with an aggressive proteolytic system (Klausner and Sitia, 1990). At the same time, it raised a new wave of exciting questions related to: (i) the mechanisms that determine substrate selection and delivery to the dislocation apparatus; (ii) the vectorial nature of retrograde transport; (iii) the role of chaperones and enzymes in substrate unfolding and presentation to the proteasomes, and (iv) the nature of the timer that allows the dislocation of misfolded molecules while sparing nascent chains or folding and assembly intermediates (Brodsky and McCracken, 1999; Plemper and Wolf, 1999).

The main features of the process of ER-associated degradation (ERAD) are outlined in Figure Figure1.1. For transmembrane proteins such as the cystic fibrosis transmembrane conductance regulator (CFTR) variant ΔF508, which is the principal cause of cystic fibrosis (Jensen et al., 1995; Ward et al., 1995), ubiquitylation of the cytosolic domain may be required for dislocation and degradation (Ward et al., 1995). Targeting of membrane-spanning substrates to proteasomes therefore seems to follow a similar mechanism to that described for cytosolic proteins. However, questions regarding how the lumenal and transmembrane domains are extracted from the ER, and what initiates the degradation of membrane proteins that, like the α-subunit of the T-cell receptor, lack ubiquitylatable cytoplasmic domains (Yu et al., 1997; Yu and Kopito, 1999), remain unanswered. Perhaps even more complex is the situation of soluble ER proteins, which are fully protected from the cytoplasmic ubiquitin/proteasome apparatus by the ER membrane. As these proteins are thought to have left the translocon (Plemper et al., 1999), mechanisms for their recruitment into functional dislocons must exist.

figure kvd05201
Fig. 1. Quality control and ER-associated degradation. Proteins that fail to successfully fold or assemble are retained in the ER and, after a given time period, dislocated through a Sec61-based channel to be degraded by cytosolic proteasomes. Substrates ...

Because integral membrane ERAD substrates are usually hydrophobic and therefore prone to aggregate upon exposure to the aqueous environment of the cytoplasm, their dislocation must be tightly coupled to proteolysis. This coupling could, in principle, be achieved by a ‘ratchet’ mechanism in which substrates are ubiquitylated or engaged by cytoplasmic factors co-dislocationally. Dislocation could also be achieved by active ‘pulling’ by proteasomes or other ATPases, which could engage their substrates while still associated with the dislocon (de Virgilio et al., 1998; Mayer et al., 1998; Chillaron and Haas, 2000; Mancini et al., 2000). The demonstration that substrates completely lacking lysine residues and, hence, internal ubiquitylation sites, are efficiently dislocated and degraded, argues against a requirement for co-dislocational ubiquitylation (Yu et al., 1997). On the other hand, the fact that some deglycosylated ERAD substrates accumulate in the cytosol (often as high molecular weight aggregates) in the absence of functional proteasomes, suggests that coupling of dislocation to proteolysis is not obligatory. It is therefore likely that sophisticated tug-of-war games are played around the Sec61 complex when polypeptides are engaged in the exit from the ER lumen. The result of these games is likely to dictate vectorial nature, efficiency of transport, and the functional coupling of dislocation and degradation.

When things go wrong

If the rate of synthesis of a given protein exceeds the combined rates of folding and degradation, some of the protein will be unable to proceed along the secretory pathway and, inevitably, will cause cellular indigestion in one or more compartment as it accumulates. This indigestion may be exacerbated by mutations that interfere with protein folding and by environmental stress. Two steps are critical in the disposal of ER-synthesized proteins: extraction from the lumen and degradation by the proteasome. While inefficiency in the former will result in accumulation in the ER, reduced degradation with normal dislocation will cause substrate deposition in the cytosol (Figure (Figure2).2). A number of diseases with apparently unrelated causes are accompanied by the presence of dilated ER cisternae containing mutated proteins. This feature suggests a common pathogenesis for these ER storage diseases (ERSD, see Kim and Arvan, 1998 for a comprehensive review). On the other hand, the growing number of pathological conditions characterized by the presence of cytosolic protein depositions and aggregates manifest themselves in a variety of pathogenic outcomes.

figure kvd05202
Fig. 2. Cellular indigestion. Dislocation and degradation are critical steps for the disposal of misfolded proteins in the ER. Failure of the former may perturb homeostasis, leading to the accumulation and aggregation of proteins in the ER lumen. Aggregates, ...

Russell bodies

More than 100 years ago, Russell (1890) described peculiar intracellular structures that he thought were fungi representing the etiological agent of cancer. It is now generally accepted that Russell bodies (RB) are dilated ER cisternae containing condensed immunoglobulins (Ig). As to their biogenesis, it was shown that the synthesis of a mutated Ig, which is neither secreted nor degraded, is sufficient to induce RB formation in cells of different species and histotype (Valetti et al., 1991). Structurally, RB are generally separated from the normal ER network (Figure (Figure3A).3A). While calnexin and ribosomes are associated with RB membranes, soluble ER resident proteins such as BiP, PDI and ERp72 tend to be excluded from the lumen (Valetti et al., 1991; C. Valetti, C. Fagioli, L. Mattioli and R. Sitia, unpublished data), suggesting the existence of sorting mechanisms facilitating the segregation of insoluble aggregates that might otherwise disrupt the secretory pathway.

figure kvd05203
Fig. 3. Russell bodies and aggresomes. (A) Electron micrographs of myeloma cells expressing mutated IgM in which the µ chain lacks the first constant domain (courtesy of C. Grossi, L. Mattioli, C. Tacchetti and C. Valetti, University of Genova, ...

RB were originally described in plasma cells (Maldonado et al., 1966), and their frequency in this cell type probably correlates with the fact that Ig genes undergo somatic hypermutation. However, dilated ER cisternae containing condensed aberrant proteins are found in secretory cells of different origin, suggesting condensation of transport-incompetent proteins in the ER as the common cause for this morphological feature. Many disease-linked cases of intralumenal protein accumulation have been described (Kim and Arvan, 1998) including thyrocytes of congenital goiter patients and hepatocytes of individuals carrying mutated α1 anti-trypsin alleles (PiZ).

The correlation between liver disease and PiZ lumenal depositions (Carlson et al., 1989) indicates that the latter can be harmful for cells, but the exact mechanisms that lead to toxicity are not known. Protein deposits in the ER may disturb membrane traffic, generate deleterious signals, or induce an unfolded protein response (UPR; see Travers et al., 2000, and references therein). Not only the abundance, but also the nature of the substrate seems to be important. For example, transfectants that accumulate Factor VIII in the ER lumen induce a robust UPR (Dorner et al., 1989). In contrast, chimeric proteins engineered to form conditional aggregates in the ER (by pharmacological treatment) do not show signs of ER stress (Rivera et al., 2000), perhaps because they do not sequester chaperone molecules. Indeed, ER stress sensors, like PERK and IRE1, are apparently able to sense the levels of free BiP (Bertolotti et al., 2000). In some cases, the anatomy of the ER is restored by relief of the restrictive condition, clearly indicating that cells can recover (Pacifici and Iozzo, 1988). Moreover, in plants, the formation of aggregates in the ER seems to be part of the normal developmental program for the storage of specific proteins (Galili et al., 1998). RB are not the sole form of protein accumulation in specialized ER subregions (Sitia and Meldolesi, 1992). For instance, BiP relocalizes into a punctate pattern (BiP bodies) when ER–Golgi transport is perturbed in yeast (Nishikawa et al., 1994). Recent evidence suggests that transport-competent cargo proteins may be concentrated by interaction with appropriate receptors prior to exiting the ER (see Hendershot, 2000, and references therein).

How are RBs and related structures disposed of? In pancreatic cells, which do not divide rapidly, intracisternal granules containing aggregated zymogens are eventually fused with lysosomes (Tooze et al., 1990). This may also be the case for mutant PiZ retained in the endoplasmic reticulum (J.H. Teckman and D.H. Perlmutter, personal communication). Autophagic vacuoles may be formed when cell division is not sufficient to avoid levels of accumulation incompatible with the maintenance of the proper cellular architecture.

One could speculate that in the tug-of-war model described above, certain proteins, e.g. unassembled Ig heavy chains (Mancini et al., 2000), might be intrinsically difficult to dislocate to the cytosol either because they establish interactions with ER chaperones, or because they form aggregates. As discussed above, mechanisms are likely to exist that concentrate substrates in the vicinity of the dislocon and favor their partial unfolding to facilitate passage through the ER membrane. When the dislocation machinery is insufficient or when mutations tip the balance away from the folding pathway, these mechanisms may generate conditions favoring substrate aggregation within the lumen, leading to cisternal dilation.

Aggresomes

If the tug-of-war across the ER membrane is won by the machinery on the cytoplasmic side of the membrane, ‘dislocated’ proteins are generally rapidly degraded by proteasomes, in a tightly coupled process that presumably exploits the physical association of proteasomes and the ubiquitylation machinery (Sommer and Jentsch, 1993; Biederer et al., 1997) with the ER membrane. Dislocation of integral membrane and secretory proteins that is not coupled to rapid proteolysis poses a serious risk of cytoplasmic aggregation when these often extremely hydrophobic proteins are transiently exposed to the aqueous, reducing conditions in the cytosol. For example, dislocation of highly expressed integral membrane proteins like the ΔF508 mutant form of CFTR leads to the formation of indigestible cytoplasmic aggregates, which are sequestered within inclusion bodies called aggresomes (Johnston et al., 1998). While RB reflect accumulation within the ER lumen, aggresomes are a symptom of cytoplasmic indigestion.

Aggresomes are formed around the microtubule organizing center (MTOC) by active minus end-directed transport of misfolded protein on microtubules (Figure (Figure2).2). Their formation is prevented by disruption of the dynein–dynactin complex by overexpression of p50/dynamitin, implicating cytoplasmic dynein as the motor in this transport process (Garcia-Mata et al., 1999). Aggresomes are also distinguished by the presence of a cage of intermediate filament (IF) proteins, like vimentin, which are displaced from their normal cellular distribution upon loss of proteasome activity (Johnston et al., 1998). Aggresomes are also variably enriched for proteasome subunits, ubiquitin and molecular chaperones (Johnston et al., 1998; Garcia-Mata et al., 1999; Wigley et al., 1999), consistent with their formation in response to cellular stress.

Johnston et al. (1998) first proposed that aggresome formation is part of a general cytoplasmic response to aggregated protein. Such aggregates could form when the synthesis of aggregation-prone proteins exceeds the capacity of cytoplasmic chaperone and proteolytic systems, either as a result of overexpression, or by the acquisition of mutations that alter the balance between folding and misfolding. Thus, cytoplasmic indigestion can result from acquired or inherited deficiencies in the digestive machinery itself, from toxic food, or from simple gluttony.

Consistent with the role described above, aggresomes have been shown to form in response to the presence of aggregated forms of misfolded cytoplasmic proteins as well as to dislocated variants of transmembrane proteins such as CFTR and presenilin (Garcia-Mata et al., 1999). Indeed, the formation of aggresome-like structures was previously described by Wojcik and co-workers as a response to proteasome inhibition (Wojcik et al., 1996; Wojcik, 1997). These structures were characterized by deposits of proteinaceous material, ubiquitin and proteasome subunits around the microtubule organizing center of HeLa cells. Spontaneous aggresome-like inclusions containing reorganized vimentin IFs and Hsp70 surround the MTOC of Epstein–Barr virus (EBV)-transformed lymphoblastoid cells in the absence of any chemical proteasome inhibitors (Laszlo et al., 1991). Intriguingly, the EBV-encoded nuclear antigen (EBNA1) has been shown to inhibit proteolysis by the ubiquitin/proteasome pathway (as part of the virus’ strategy to evade presentation by class I MHC; Levitskaya et al., 1997; Ploegh, 1998), suggesting that viral infection can promote cellular indigestion.

What is the difference between ‘aggresomes’ and ‘inclusion bodies’, which form in microorganisms upon overexpression of exogenous protein? Both types of structures reflect strategies to sequester misfolded proteins within the cytoplasm. However, the relatively large size of animal cells, together with the presence of a cytomatrix that restricts the diffusional mobility of large particles (Gershon et al., 1985), suggests that non-diffusional mechanisms are required to segregate or sequester protein aggregates within the cytoplasm. Formation of aggresomes, unlike generic inclusion bodies, exploits transport on microtubules; disruption of either the microtubule cytoskeleton or the retrograde motor leads to the deposition of dispersed inclusions throughout the cytoplasm (Garcia-Mata et al., 1999). A second distinguishing feature of aggresomes is the presence of displaced type III IF like vimentin, which relocates from its normal extended cytoplasmic distribution, ‘collapsing’ to form a dense cage-like structure around the pericentriolar mass of aggregated protein. The normal function of vimentin is obscure; cells and even knock-out mice seem to survive well without it (Colucci-Guyon et al., 1994). Although it is not clear whether the vimentin collapse contributes to the formation or the stabilization of aggresomes, it is a consistent feature that distinguishes aggresomes from other types of inclusion bodies.

Cytoplasmic inclusion bodies resembling aggresomes are common cytopathological features of neurons and glia in many human neurodegenerative diseases (Alves-Rodrigues et al., 1998; Tran and Miller, 1999). These inclusions, like aggresomes, are enriched in proteasome subunits, molecular chaperones, ubiquitin conjugates and displaced intermediate filaments. While the vast majority of common neurodegenerative disorders are of idiopathic origin, some have been characterized and are caused by toxic ‘gain of function’ mutations in known genes that encode abundant cytoplasmic proteins such as α-synuclein, in the case of Parkinson’s disease (Polymeropoulos et al., 1997), and superoxide dismutase (SOD1) in the case of familial amyotrophic lateral sclerosis (Rosen et al., 1993). The correlation between missense mutations in these genes and the formation of cytoplasmic inclusion bodies containing aggregated forms of their protein products establishes a tight linkage between cellular indigestion and neurodegeneration.

Perspectives

It is becoming evident that protein folding in cells is not highly efficient (Schubert et al., 2000), and that full-time cooperation between proteolytic and chaperone systems in different cellular compartments provides a measure of immunity against toxic protein aggregates (Casagrande et al., 2000; Gething, 2000; Travers et al., 2000). Still, the cellular digestive tract can become overwhelmed or dysfunctional, resulting in manifestations of cellular indigestion including the formation of aggresomes and Russell bodies. Whether these structures are part of the pathology, or reflect protective ‘containment’ strategies, is food for thought and for future research.

figure kvd05204
figure kvd05205

Acknowledgements

We thank the members of our laboratories for generating data, ideas, criticism and enthusiasm, AIRC, CNR, Ministero della Sanità, NIH-NIDDK and GM for funding our research, the chefs of the banquet at the 1999 ECBO meeting in Bologna for providing the culinary inspiration (without indigestion) for this review and Stefania Trinca for secretarial assistance. We also thank Connie Wong for her artist’s impression of protein transport across membranes (see table of contents). We apologize to the many colleagues whose excellent work we could not cite solely for limits of space.

Footnotes

Ron R. Kopito and Roberto Sitia

References

  • Alves-Rodrigues A., Gregori, L. and Figueiredo-Pereira, M.E. (1998) Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci., 21, 516–520. [PubMed]
  • Bertolotti A., Zhang, Y., Hendershot, L.M., Harding, H.P. and Ron, D. (2000) Dynamic interaction of BiP and ER stress transducers in the unfolded protein response. Nature Cell Biol., 2, 326–332. [PubMed]
  • Biederer T., Volkwein, C. and Sommer, T. (1997) Role of Cue1p in ubiquitination and degradation at the ER surface. Science, 278, 1806–1809. [PubMed]
  • Brodsky J.L. and McCracken, A.A. (1999) ER protein quality control and proteasome-mediated protein degradation. Semin. Cell Dev. Biol., 10, 507–513. [PubMed]
  • Carlson J.A., Rogers, B.B., Sifers, R.N., Finegold, M.J., Clift, S.M., DeMayo, F.J., Bullock, D.W. and Woo, S.L. (1989) Accumulation of PiZ α1-antitrypsin causes liver damage in transgenic mice. J. Clin. Invest., 83, 1183–1190. [PMC free article] [PubMed]
  • Casagrande R., Stern, P., Diehn M., Shamu C., Osario M., Zùñiga M., Brown P.O. and Ploegh, H. (2000) Degradation of proteins from the ER of S.cerevisiae requires an intact unfolded response pathway. Mol. Cell, 5, 729–735. [PubMed]
  • Chillaron J. and Haas, I.G. (2000) Dissociation from BiP and retrotranslocation of unassembled immunoglobulin light chains are tightly coupled to proteasome activity. Mol. Biol. Cell, 11, 217–226. [PMC free article] [PubMed]
  • Colucci-Guyon E., Portier, M.M., Dunia, I., Paulin, D., Pournin, S. and Babinet, C. (1994) Mice lacking vimentin develop and reproduce without an obvious phenotype. Cell, 79, 679–694. [PubMed]
  • de Virgilio M., Weninger, H. and Ivessa, N.E. (1998) Ubiquitination is required for the retro-translocation of a short-lived luminal endoplasmic reticulum glycoprotein to the cytosol for degradation by the proteasome. J. Biol. Chem., 273, 9734–9743. [PubMed]
  • Dorner A.J., Wasley, L.C. and Kaufman, R.J. (1989) Increased synthesis of secreted proteins induces expression of glucose-regulated proteins in butyrate-treated Chinese hamster ovary cells. J. Biol. Chem., 264, 20602–20607. [PubMed]
  • Ellgaard L., Molinari, M. and Helenius, A. (1999) Setting the standards: quality control in the secretory pathway. Science, 286, 1882–1888. [PubMed]
  • Galili G., Sengupta-Gopalan, C. and Ceriotti, A. (1998) The endoplasmic reticulum of plant cells and its role in protein maturation and biogenesis of oil bodies. Plant Mol. Biol., 38, 1–29. [PubMed]
  • Garcia-Mata R., Bebok, Z., Sorscher, E.J. and Sztul, E.S. (1999) Characterization and dynamics of aggresome formation by a cytosolic GFP–chimera. J. Cell Biol., 146, 1239–1254. [PMC free article] [PubMed]
  • Gershon N.D., Porter, K.R. and Trus, B.L. (1985) The cytoplasmic matrix: its volume and surface area and the diffusion of molecules through it. Proc. Natl Acad. Sci. USA, 82, 5030–5034. [PMC free article] [PubMed]
  • Gething M.J. (2000) Presenilin mutants subvert chaperone function. Nature Cell Biol., 2, E21–E23. [PubMed]
  • Hendershot L.M (2000). Giving protein traffic the green light. Nature Cell Biol., 2, 105–106. [PubMed]
  • Jensen T.J., Loo, M.A., Pind, S., Williams, D.B., Goldberg, A.L. and Riordan, J.R. (1995) Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell, 83, 129–135. [PubMed]
  • Johnston J.A., Ward, C.L. and Kopito, R.R. (1998) Aggresomes: a cellular response to misfolded proteins. J. Cell Biol., 143, 1883–1888. [PMC free article] [PubMed]
  • Kim P.S. and Arvan, P. (1998) Endocrinopathies in the family of endoplasmic reticulum (ER) storage diseases: disorders of protein trafficking and the role of ER molecular chaperones. Endocrinol. Rev., 19, 173–202. [PubMed]
  • Kirschner M. (1999) Intracellular proteolysis. Trends Cell Biol., 9, M42–M45. [PubMed]
  • Klausner R.D. and Sitia, R. (1990) Protein degradation in the endoplasmic reticulum. Cell, 62, 611–614. [PubMed]
  • Kopito R.R. (1997) ER quality control: the cytoplasmic connection. Cell, 88, 427–430. [PubMed]
  • Laszlo L., Tuckwell, J., Self, T., Lowe, J., Landon, M., Smith, S., Hawthorne, J.N. and Mayer, R.J. (1991) The latent membrane protein-1 in Epstein–Barr virus-transformed lymphoblastoid cells is found with ubiquitin–protein conjugates and heat-shock protein 70 in lysosomes oriented around the microtubule organizing centre. J. Pathol., 164, 203–214. [PubMed]
  • Levitskaya J., Sharipo, A., Leonchiks, A., Ciechanover, A. and Masucci, M.G. (1997) Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein–Barr virus nuclear antigen 1. Proc. Natl Acad. Sci. USA, 94, 12616–12621. [PMC free article] [PubMed]
  • Maldonado J.E., Brown, A.L., Jr, Bayrd, E.D. and Pease, G.L. (1966) Cytoplasmic and intranuclear electron-dense bodies in the myeloma cell. Arch. Pathol., 81, 484–500. [PubMed]
  • Mancini R., Fagioli, C., Fra, A.M., Maggioni, C. and Sitia, R. (2000) Degradation of unassembled soluble Ig subunits by cytosolic proteasomes: evidence that retrotranslocation and degradation are coupled events. FASEB J., 14, 769–778. [PubMed]
  • Mayer T.U., Braun, T. and Jentsch, S. (1998) Role of the proteasome in membrane extraction of a short-lived ER-transmembrane protein. EMBO J., 17, 3251–3257. [PMC free article] [PubMed]
  • Nishikawa S., Hirata, A. and Nakano, A. (1994). Inhibition of endoplasmic reticulum (ER)-to-Golgi transport induces relocalization of binding protein (BiP) within the ER to form the BiP bodies. Mol. Biol. Cell, 5, 1129–1134. [PMC free article] [PubMed]
  • Pacifici M. and Iozzo, R.V. (1988) Remodeling of the rough endoplasmic reticulum during stimulation of procollagen secretion by ascorbic acid in cultured chondrocytes. A biochemical and morphological study. J. Biol. Chem., 263, 2483–2492. [PubMed]
  • Pilon M., Schekman, R. and Romisch, K. (1997) Sec61p mediates export of a misfolded secretory protein from the endoplasmic reticulum to the cytosol for degradation. EMBO J. 16, 4540–4548. [PMC free article] [PubMed]
  • Plemper R.K. and Wolf, D.H. (1999) Retrograde protein translocation: ERADication of secretory proteins in health and disease. Trends Biochem. Sci., 24, 266–270. [PubMed]
  • Plemper R.K., Deak, P.M., Otto, R.T. and Wolf, D.H. (1999) Re-entering the translocon from the lumenal side of the endoplasmic reticulum. Studies on mutated carboxypeptidase yscY species. FEBS Lett., 443, 241–245. [PubMed]
  • Ploegh H.L. (1998) Viral strategies of immune evasion. Science, 280, 248–253. [PubMed]
  • Polymeropoulos M.H. et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science, 276, 2045–2047. [PubMed]
  • Rivera V.M. et al. (2000) Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum. Science, 287, 826–830. [PubMed]
  • Rivett A.J. (1998) Intracellular distribution of proteasomes. Curr. Opin. Immunol., 10, 110–114. [PubMed]
  • Rosen D.R. et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 362, 59–62. [PubMed]
  • Russell W. (1890) Address on a characteristic organism of cancer. Br. Med. J., 2, 1356–1360. [PMC free article] [PubMed]
  • Schubert U., Anton, L.C., Gibbs, J., Norbury, C.C., Yewdell, J.W. and Bennink, J.R. (2000) Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature, 404, 770–774. [PubMed]
  • Sitia R. and Meldolesi, J. (1992). Endoplasmic reticulum: a dynamic patchwork of specialized subregions. Mol. Biol. Cell, 10, 1067–1072. [PMC free article] [PubMed]
  • Sommer T. and Jentsch, S. (1993) A protein translocation defect linked to ubiquitin conjugation at the endoplasmic reticulum. Nature, 365, 176–179. [PubMed]
  • Tooze J., Hollinshead, M., Ludwig, T., Howell, K., Hoflack, B. and Kern, H. (1990) In exocrine pancreas, the basolateral endocytic pathway converges with the autophagic pathway immediately after the early endosome. J. Cell Biol., 111, 329–345. [PMC free article] [PubMed]
  • Tran P.B. and Miller, R.J. (1999) Aggregates in neurodegenerative disease: crowds and power? Trends Neurosci., 22, 194–197. [PubMed]
  • Travers K.J., Patil, C.K., Wodicka, L., Lockhart, D.J., Weissman, J.S. and Walter, P. (2000) Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated protein degradation. Cell, 101, 249–258. [PubMed]
  • Valetti C., Grossi, C.E., Milstein, C. and Sitia, R. (1991) Russell bodies: a general response of secretory cells to synthesis of a mutant immunoglobulin which can neither exit from, nor be degraded in, the endoplasmic reticulum. J. Cell Biol., 115, 983–994. [PMC free article] [PubMed]
  • Ward C.L., Omura, S. and Kopito, R.R. (1995) Degradation of CFTR by the ubiquitin-proteasome pathway. Cell, 83, 121–127. [PubMed]
  • Wickner S., Maurizi, M.R. and Gottesman, S. (1999) Posttranslational quality control: folding, refolding, and degrading proteins. Science, 286, 1888–1893. [PubMed]
  • Wiertz E.J., Tortorella, D., Bogyo, M., Yu, J., Mothes, W., Jones, T.R., Rapoport, T.A. and Ploegh, H.L. (1996) Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature, 384, 432–438. [PubMed]
  • Wigley W.C., Fabunmi, R.P., Lee, M.G., Marino, C.R., Muallem, S., DeMartino, G.N. and Thomas, P.J. (1999) Dynamic association of proteasomal machinery with the centrosome. J. Cell Biol., 145, 481–490. [PMC free article] [PubMed]
  • Wojcik C. (1997) An inhibitor of the chymotrypsin-like activity of the proteasome (PSI) induces similar morphological changes in various cell lines. Folia Histochem. Cytobiol., 35, 211–214. [PubMed]
  • Wojcik C., Schroeter, D., Wilk, S., Lamprecht, J. and Paweletz, N. (1996) Ubiquitin-mediated proteolysis centers in HeLa cells: indication from studies of an inhibitor of the chymotrypsin-like activity of the proteasome. Eur. J. Cell Biol., 71, 311–318. [PubMed]
  • Yu H., Kaung, G., Kobayashi, S. and Kopito, R.R. (1997) Cytosolic degradation of T-cell receptor α chains by the proteasome. J. Biol. Chem., 272, 20800–20804. [PubMed]
  • Yu H. and Kopito, R.R. (1999) The role of multiubiquitination in dislocation and degradation of the α subunit of the T cell antigen receptor. J. Biol. Chem., 274, 36852–36858. [PubMed]

Articles from EMBO Reports are provided here courtesy of The European Molecular Biology Organization
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links